Gout
A review and meta-analysis assessed the influence of SGLT2i therapy on clinically relevant hyperuricemic events.
A study examined the relationship between gout and kidney stones using NHANES data.
Researchers examined ULT and the risk of CKD progression among patients with impaired kidney function and gout.
What is the association of gout with CV disease and mortality risk in patients with type 2 diabetes and can CKD modify it?
The EMPA-KIDNEY trial examined the effects of SGLT2 inhibition on uric acid and gout in patients with CKD.
A study examined whether urate-lowering therapy (ULT) for gout might help delay progression of chronic kidney disease (CKD).
Researchers evaluated efficacy and safety of allopurinol versus febuxostat for gout in patients with stage 3 CKD.
Recognizing and managing concurrent gout and CKD is important for improving outcomes but can be difficult.
There are few data available on the associations between serum urate levels and the risk of recurrent gout.
A study found notable lipid profile changes in hyperuricemia and early-onset gout.
Pharmacologic activation of Nrf2 alleviates gout by inhibiting oxidative stress, reducing joint inflammation.
Metabolic syndrome is strongly linked to hyperuricemia in both genders, especially in women.
Advertisement
Advertisement
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.